The hemorrhage risk of dasatinib therapy

In this issue of Blood, Kaiser et al(1) pinpoint the glycoprotein IIb (GPIIB)/G alpha(13)/Src tyrosine kinase (c-Src)/14-3-3 zeta signaling axis as a requirement for platelet migration and shed light on how the antineoplastic oral tyrosine kinase inhibitor dasatinib increases the risk of inflammation-associated mucosal hemorrhage.